Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis
Clinical trial NCT02595970 · COMPLETED
Trial details
- NCT number
- NCT02595970
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-05-20
- Primary completion
- 2017-02-09
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.